Estrogen is primarily an anti-inflammatory hormone, but it can also promote inflammation under certain conditions. The answer depends on how much estrogen is present, which receptors it activates, and what’s already happening in your body. This dual nature explains why estrogen protects against inflammation in some situations while worsening it in others.
Estrogen Is Mostly Anti-Inflammatory
At normal physiological levels, estrogen suppresses several key inflammatory signals. It blocks a major inflammation pathway called NF-kB, which is the switch cells use to ramp up production of inflammatory proteins like TNF-alpha and interleukin-6. When estrogen binds to its primary receptor (known as ER-alpha), it prevents this switch from flipping on. In lab studies, macrophages that lack this receptor produce significantly more TNF-alpha when exposed to bacterial toxins, confirming that estrogen’s anti-inflammatory action depends heavily on this receptor.
Estrogen also reduces production of interleukin-8, a chemical that recruits immune cells to sites of inflammation, and pushes immune cells called macrophages toward a calmer, repair-oriented state rather than an aggressive attack mode. In animal models of arthritis, estrogen lowers both TNF-alpha and interleukin-6 from T cells and reduces inflammatory signals in joint tissue.
You can actually see this effect play out during the menstrual cycle. A large study tracking women across their cycles found that C-reactive protein (CRP), a standard blood marker of inflammation, was highest during menstruation when estrogen is at its lowest. CRP dropped to its lowest point around ovulation, when estrogen peaks. A tenfold increase in estradiol, which is a typical swing during a normal cycle, was associated with a 24% decrease in CRP. This pattern held after accounting for age, weight, race, and other hormones.
When Estrogen Promotes Inflammation
The same hormone that calms inflammation in many contexts can fuel it in others. The clearest example is autoimmune disease. Systemic lupus erythematosus (SLE) affects women far more often than men, and estrogen appears to be part of the reason. In lupus patients, estradiol increases levels of specific microRNAs that suppress a protein called SRSF1 in T cells. When SRSF1 drops, the immune system becomes overactive, producing characteristics of autoimmune disease and worsening kidney inflammation. Estradiol also downregulates a gene critical for immune self-tolerance, essentially making it harder for the immune system to distinguish the body’s own tissue from foreign invaders.
Endometriosis is another condition where estrogen drives a vicious inflammatory cycle. In endometriotic tissue, estrogen stimulates production of prostaglandin E2, a potent inflammatory molecule, through an enzyme called COX-2. Prostaglandin E2, in turn, stimulates more estrogen production. This positive feedback loop means that in endometriotic tissue, estrogen and inflammation continuously amplify each other, sustaining chronic pain and tissue growth.
There’s also a concentration effect that matters. In one study, estradiol suppressed TNF-alpha from immune cells when those cells were already activated by bacterial toxins. But the same estradiol had a stimulating effect on cytokine release when the immune cells were in a resting, non-inflamed state. In other words, estrogen can nudge inflammation upward when things are quiet and push it downward when things are already inflamed.
The Receptor That Changes Everything
Estrogen doesn’t act as a single signal. It works through three different receptors, and each one can push the immune system in a different direction. ER-alpha and a receptor called GPER are consistently linked to anti-inflammatory effects. The third receptor, ER-beta, is less predictable. Some studies show it reducing inflammation similarly to ER-alpha, while others find that a higher ratio of ER-beta is associated with pro-inflammatory patterns.
This receptor split is especially relevant in endometriosis, where ER-beta is overexpressed in the abnormal tissue. ER-beta stimulates prostaglandin production through COX-2, blocks the normal cell death process that would clear the tissue, and suppresses the protective effects of ER-alpha. The same hormone, estradiol, acts differently depending on which receptor is dominant in a given tissue. This is a major reason why estrogen can be protective in blood vessels and joints while being destructive in endometriotic lesions.
What Happens When Estrogen Drops at Menopause
The loss of estrogen’s anti-inflammatory effects after menopause contributes to the low-grade chronic inflammation associated with aging. Without estrogen keeping NF-kB signaling in check, inflammatory cytokines like interleukin-6 and TNF-alpha rise. Estrogen deficiency also increases inflammation in blood vessel walls, which is one reason cardiovascular risk climbs after menopause.
Hormone replacement therapy (HRT) can modulate these effects, but the delivery method matters significantly. Oral estrogen reduces circulating levels of interleukin-6, TNF-alpha, and several cell adhesion molecules involved in vascular inflammation. However, oral estrogen also raises CRP levels, which initially alarmed researchers. That CRP increase now appears to be a metabolic byproduct of estrogen passing through the liver on first pass rather than a sign of actual increased inflammation in the body. Transdermal estrogen (patches or gels) avoids this liver effect entirely. Studies show transdermal estrogen either leaves CRP unchanged or slightly lowers it, while still providing the anti-inflammatory benefits seen with oral forms.
Why the Answer Isn’t Simple
As one major review in Endocrine Reviews summarized, there is an “unresolved paradox” in estrogen’s relationship with inflammation. Estrogen suppresses bone loss and calms inflammation in many chronic disease models. Yet it also supports immune activation after trauma and worsens certain autoimmune conditions. A uniform rule for how estrogen affects inflammation across all diseases simply doesn’t exist.
What determines the outcome is a combination of factors: the concentration of estrogen present, which receptors are dominant in the tissue, whether the immune system is already activated, and the specific disease context. For most healthy tissue at normal hormone levels, estrogen acts as a brake on inflammation. In autoimmune-prone individuals, in endometriotic tissue with altered receptor ratios, or at unusual concentrations, that brake can become an accelerator. The hormone itself isn’t inherently inflammatory or anti-inflammatory. The context it acts in decides which role it plays.